Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 5/20 | 0.36 |
| ▸ | NMT2 | O60551 | 4/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30801495 | 1.00 | PTGS1 (0.44) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29375029 | 0.97 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29475226 | 0.97 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30662067 | 0.97 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29509632 | 0.97 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL31018946 | 0.97 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29350894 | 0.97 | PTGS1 (0.47) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL30923419 | 0.95 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29356041 | 0.95 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA | |
| SCHEMBL29360266 | 0.95 | PTGS1 (0.43) | PTGS1GSTK1GLO1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116917482-A | Chimeric proteins and methods of treating central nervous system disorders | 银溪制药股份有限公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2026105066-A1 | METHODS AND COMPOSITIONS FOR CHARACTERIZING PROTEINS | CAMBRIDGE GENETIX LTD (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-12577305-B2 | Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof | ITABMED (HK) LIMITED (CN) | 2026-03-17 | — | — | US | disclosed |
| US-12570748-B2 | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof | CYTOMX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12498367-B2 | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof | CYTOMX THERAPEUTICS, INC. | 2025-12-16 | — | — | US | disclosed |
| US-12459999-B2 | Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof | CYTOMX THERAPEUTICS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12460000-B2 | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof | ITABMED (HK) LIMITED (CN) | 2025-11-04 | — | — | US | disclosed |
| EP-3535300-B1 | ACTIVATABLE ANTI-CTLA-4 ANTIBODIES AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12441799-B2 | Activatable anti-CTLA-4 antibodies and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4176896-B1 | MATRIPTASE AND U-PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-11279924-B2 | Conditionally active polypeptides and methods of generating them | BIOATLA, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3966250-A2 | PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF | Immunorizon Ltd. (IL) | 2022-03-16 | — | — | EP | disclosed |
| EP-3247393-B1 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3406633-B1 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME | CYTOMX THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-108026170-B | anti-CD 71 antibodies, activatable anti-CD 71 antibodies, and methods of use thereof | 西托姆克斯治疗公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11254932-B2 | Conditionally active biological proteins | BIOATLA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-108112254-B | anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof | 西托姆克斯治疗公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20220023439-A1 | ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-11229639-B2 | Camptothecin derivatives | IMMUNOGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230610-B2 | Bivalent antibodies masked by coiled coils | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12498367-B2 | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof | FCGR3B, FCGR2A, FCGR1A | PTGS1 2993/4885GSTK1 581/4885GLO1 3394/4885 |
| US-12570748-B2 | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof | ADAM8, PREP, MMP24 | PTGS1 2503/4885GSTK1 2549/4885GLO1 2068/4885 |
| US-12577305-B2 | Multispecific antigen binding proteins capable of binding CD19 and CD3, and use thereof | IGSF11, CD2BP2, CD2 | PTGS1 4646/4885GSTK1 2276/4885GLO1 3369/4885 |
| US-11230610-B2 | Bivalent antibodies masked by coiled coils | COIL, CRYAB, UACA | PTGS1 4324/4885GSTK1 975/4885GLO1 3838/4885 |
| US-11229639-B2 | Camptothecin derivatives | TOP2A, TOP2B, PCNA | PTGS1 2344/4885GSTK1 62/4885GLO1 3709/4885 |
| US-20220023439-A1 | ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF | FCGR1A, FCGR3B, FCGR2A | PTGS1 3424/4885GSTK1 2113/4885GLO1 2732/4885 |
| US-12459999-B2 | Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof | ADAM8, MMEL1, ADAM33 | PTGS1 1237/4885GSTK1 2104/4885GLO1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.